This trial will test a new combination treatment for lung cancer.
- Non-Small Cell Lung Cancer
4 Primary · 7 Secondary · Reporting Duration: 2 years
7 Treatment Groups
Tomi + Current Pembro
1 of 7
A1 Tomi + Current Pembro
1 of 7
B1 Tomi + Pembro
1 of 7
C1 Tomi + Pembro + Pemetrexed (Non-sqamous) or Tomi + Pembro (Squamous)
1 of 7
Pbo + Current Pembro
1 of 7
Pbo + Pembro
1 of 7
Pbo + Pembro + Pemetrexed (Non-sqamous) or Pbo + Pembro (Squamous)
1 of 7
180 Total Participants · 7 Treatment Groups
Primary Treatment: Tomivosertib · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18 - No maximum age · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||33.3%|
What site did they apply to?
|Texas Oncology-Baylor Charles A. Sammons Cancer Center||66.7%|
|Memorial Healthcare System||33.3%|
What portion of applicants met pre-screening criteria?
|Did not meet criteria||100.0%|
How many prior treatments have patients received?
Frequently Asked Questions
How many centers are providing access to this clinical experiment?
"This clinical trial is currently enrolling participants at 84 centres, which includes Abilene, Brooksville and Morgantown as well as 81 other sites. To reduce the burden of travel expenses, it may be beneficial to select a location nearest you when considering participation." - Anonymous Online Contributor
How many participants is this experiment enrolling in total?
"To complete this medical trial, 180 volunteers who meet the pre-determined criteria must be enrolled. Potential participants can find a clinical site in Abilene, Texas or Brooksville, West Virginia that offers participation opportunities at Texas Oncology - West Texas and ASCLEPES Research Centers respectively." - Anonymous Online Contributor
Are enrollment slots still available for this experiment?
"Affirmative. The clinicaltrials.gov database indicates that this medical research effort, first listed on June 2nd 2021, is presently recruiting patients. A total of 180 individuals must be gathered from 83 sites in order to complete the study's requirements." - Anonymous Online Contributor
To what maladies is Tomivosertib commonly prescribed?
"Tomivosertib is prescribed for the treatment of malignant neoplasms and can be used to battle conditions like unresectable melanoma, microsatellite instability high, or chemotherapy-resistant progression." - Anonymous Online Contributor
What is the aim of this clinical research?
"This two-year long medical trial aims to measure the progression-free survival (PFS) of tomivosertib when taken in conjunction with pembrolizumab as first line treatment. Secondary objectives include evaluating PFS in combination with pemetrexed and/or pembrolizumab, depending on if a patient has non-squamous or squamous NSCLC, respectively; likewise these results will be measured by assessing RECIST 1.1 response data collected by the BIRC. Additionally, each cohort (A,B & C) which are receiving different treatments involving tomivosertib plus p" - Anonymous Online Contributor
Has Tomivosertib been evaluated in other research studies?
"Tomivosertib commenced research at City of Hope a decade ago, with 381 studies completed to date. Currently there are 961 ongoing projects, the majority of which take place in Abilene, Texas." - Anonymous Online Contributor
To what extent are individuals safeguarded when taking Tomivosertib?
"Tomivosertib has been evaluated with regards to safety, and is estimated as a score of 2 on the scale. This rating indicates that while it may not be proven efficacious yet, there is data indicating its level of security." - Anonymous Online Contributor